Feasibility and clinical impact of sharing patient-reported symptom toxicities and performance status with clinical investigators during a phase 2 cancer treatment trial

BACKGROUND: Clinicians can miss up to half of patients’ symptomatic toxicities in cancer clinical trials and routine practice. Although patient-reported outcome questionnaires have been developed to capture this information, it is unclear whether clinicians will make use of patient-reported outcomes...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Clin Trials
Prif Awduron: Basch, Ethan, Wood, William A, Schrag, Deborah, Sima, Camelia S, Shaw, Mary, Rogak, Lauren J, Kris, Mark G, Shouery, Marwan, Bennett, Antonia, Atkinson, Thomas, Pietanza, M Catherine
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2015
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5228492/
https://ncbi.nlm.nih.gov/pubmed/26542025
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1740774515615540
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg